Ocugen, Inc. (OCGN) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Ocugen (OCGN) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Ocugen is a clinical-stage biotech developing modifier gene therapies for blinding eye diseases, led by OCU400 for retinitis pigmentosa, whose Phase 3 topline data are expected in the first quarter of 2027. As of October 16, 2026 the shares closed near ~$0.80, down ~41.7% year to date, for a market value of roughly ~$273 million. The thesis is that a single gene-agnostic platform could address multiple large ophthalmic markets. The biggest risk is that the company is pre-revenue and speculative: its value rests on clinical trial readouts and regulatory approvals that may not arrive, and reaching them likely requires ongoing dilution.
OCGN stock price
As of 2026-11-16, Ocugen, Inc. (OCGN) last closed at $0.7730, down 33.4% over the past year. Over the past 52 weeks it has traded between $0.7030 and $2.48.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Ocugen, Inc.'s investor relations page. Walnut is informational, not investment advice.
OCGN key stats
At $0.77 on November 16, 2026, Ocugen, Inc. (OCGN) has a market cap of $261M.
- Market cap
- $261M
- Beta
- 1.98
Market cap, P/E and yield are measured at the $0.77 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Ocugen, Inc. (OCGN)?
The last two weeks for Ocugen, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- OCGN closed at $0.77 on November 16, 2026, down 20.5% over the past five trading days (from $0.97).
- On November 10, 2026, Ocugen, Inc. filed an 8-K with the SEC reporting a material agreement and information shared with investors (Regulation FD) (Item 1.01, Item 7.01). Read the 8-K on sec.gov
- On November 4, 2026, Ocugen, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 4, 2026, Ocugen, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Ocugen, Inc. (OCGN) latest quarter
Ocugen reported revenue of $2.0 million for Q3 2026, up 11% from a year earlier (Ocugen, Nov 4, 2026).
Source: Ocugen Q3 2026 results, Nov 4, 2026. Full earnings breakdown
What does Ocugen, Inc. (OCGN) do?
Ocugen, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on gene and cell therapies for eye diseases. Its core asset is a modifier gene-therapy platform that uses nuclear hormone receptor genes to address disease across many genetic mutations rather than one at a time. The lead program, OCU400, targets broad retinitis pigmentosa in the Phase 3 liMeliGhT trial; OCU410 targets geographic atrophy secondary to dry age-related macular degeneration; and OCU410ST targets Stargardt disease. The company has framed a goal of pursuing three biologics license applications across these programs, with the first, for OCU400, now planned for the second quarter of 2027 after Phase 3 topline data in the first quarter, and also runs earlier-stage work in other modalities.
Many investors first encountered Ocugen during the pandemic, when it partnered with Bharat Biotech to seek U.S. authorization for the COVID-19 vaccine COVAXIN. That effort drove large swings in the stock but did not result in a U.S. commercial product, and the company has since pivoted its primary narrative to ophthalmic gene therapy. Today Ocugen generates no meaningful product revenue and funds operations through its cash balance and periodic capital raises, making it a high-risk, story-driven name whose price tends to move sharply around clinical and regulatory news.
The autumn of 2026 brought early ex-U.S. deals but a falling share price. On September 25, 2026 the Bahamas' Longevity and Regenerative Therapies Board granted OCU400 provisional approval and priority designation, letting Ocugen supply it through an expanded access program with a goal of treating a first patient within about 90 days. On October 14 Ocugen licensed exclusive OCU400 rights in the Middle East and North Africa to Roots Pharmaceutical for up to ~$4 million of upfront and early development payments, up to ~$255 million of sales milestones and royalties equal to 22% of net sales, with Ocugen manufacturing commercial supply. The stock still fell ~38.1% over three months and ~50.0% over one year, closing at ~$0.80 on October 16, 2026, below the $1.00 minimum bid price Nasdaq requires for continued listing.
What's driving Ocugen, Inc. (OCGN)?
Lead program advancing toward a regulatory decision
OCU400 for broad retinitis pigmentosa completed enrollment in its Phase 3 liMeliGhT trial in early 2026. The company had earlier guided to a rolling BLA filing beginning in the third quarter of 2026; its September 2026 releases instead point to topline Phase 3 data in the first quarter of 2027 and a U.S. BLA submission planned for the second quarter of 2027. OCU400 carries FDA Regenerative Medicine Advanced Therapy and Orphan Drug designations and an EMA orphan designation. Prior Phase 1/2 data showed durable, gene-agnostic visual benefit over three years. A clear lead asset with a defined regulatory path is the central pillar of the bull case.
A platform, not a single shot on goal
Ocugen's modifier gene-therapy approach is gene-agnostic, meaning one therapy aims to treat patients regardless of which specific mutation causes their disease. Beyond OCU400, the company is advancing OCU410 for geographic atrophy and OCU410ST for Stargardt disease, giving it multiple independent readouts. Platform breadth means a single program's success or failure does not have to define the whole company.
Large, underserved eye-disease markets
Retinitis pigmentosa, geographic atrophy in dry AMD, and Stargardt disease collectively affect a substantial patient population with limited or no disease-modifying options. Ocugen has reported preliminary Phase 2 data for OCU410 showing reduced lesion growth versus control. If any program reaches approval, the addressable markets are meaningful, which is the core of the long-term opportunity.
Binary catalysts can re-rate the stock quickly
Because Ocugen is pre-commercial, its value is concentrated in upcoming events: trial readouts, regulatory filings, and agency feedback. Positive surprises can drive sharp upward moves, while disappointments can do the reverse. This catalyst-heavy profile is why the stock is volatile and why position sizing matters more than usual.
Ex-U.S. access and licensing before a U.S. approval
Ocugen has started to monetize OCU400 outside the U.S. ahead of the Phase 3 readout. The Bahamas granted provisional approval and priority designation on September 25, 2026 under its Longevity and Regenerative Therapies Act, with supply through an expanded access program. On October 14 the company signed an exclusive MENA license with Roots Pharmaceutical worth up to ~$4 million near term, up to ~$255 million in sales milestones and a 22% royalty on net sales. In early October it also named Jolanda Crombach general manager of its European affiliate. These deals bring little cash today, but they show a commercial plan forming around the lead program.
What are the risks to Ocugen, Inc. (OCGN)?
Ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval. The company funds itself from a limited cash balance and recurring capital raises, and it has historically issued equity and convertible debt that dilute existing shareholders. It competes with larger, better-funded gene-therapy and ophthalmology developers. A single negative readout or regulatory setback could sharply reduce the stock's value. Two newer risks apply as of October 2026. The shares closed at ~$0.80 on October 16, below Nasdaq's $1.00 minimum bid requirement, and a sustained period under that level can trigger a deficiency notice and, if not cured, a reverse split or delisting. The U.S. BLA timeline has also moved out, from a rolling filing guided for the third quarter of 2026 to a planned submission in the second quarter of 2027, which lengthens the period the company must fund before any U.S. approval decision.
What is the Ocugen, Inc. (OCGN) forecast?
6 analysts publish price targets on OCGN, averaging $12.17 as of November 2026, or +1480.5% against the $0.77 share price on November 16, 2026. The published targets run from $8.00 to $22.00, a wide spread, and the ratings split 6 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full OCGN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is OCGN a buy or a sell?
We give no verdict on Ocugen, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Lead program advancing toward a regulatory decision. OCU400 for broad retinitis pigmentosa completed enrollment in its Phase 3 liMeliGhT trial in early 2026. The most optimistic published target, $22.00, assumes this works close to its best case.
The case against. Ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval. The most pessimistic target, $8.00, is roughly what OCGN is worth if this bites instead.
Read the full bull and bear case on OCGN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Ocugen, Inc. (OCGN) split its stock?
Yes. Ocugen, Inc. (OCGN) has had one share split in the last 10 years:
- 1:60 on September 30, 2019, so every share held became 0.016666666666666666 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of OCGN the day before the 1:60 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Ocugen, Inc. (OCGN) valued?
Market cap, P/E and dividend yield at today's price are in the OCGN key stats above. The business figures below come from Ocugen, Inc.'s reported results as of October 2026 and change when it next reports.
- Shares outstanding: ~339 million
- Revenue (TTM, collaboration/other): ~$4.6 million
- Net loss (TTM): ~$81.8 million (~$0.26 per share)
- Q2 2026 net loss: ~$24.9 million; EPS -$0.06 vs -$0.05 consensus
- Cash (June 30, 2026): ~$100 million, against ~$88 million of debt
- Operating cash burn (TTM): ~$61 million
As of October 2026: Ocugen is pre-profit and has no product revenue, so traditional earnings metrics do not apply; what matters is cash runway versus burn. Cash of ~$100 million at June 30, 2026 followed the 2026 convertible note offering, which management said would extend the runway into 2028, while trailing operating cash outflow ran ~$61 million and the second-quarter loss widened to ~$24.9 million. Analysts expect a loss of about $0.05 per share for the third quarter, with results expected around November 5, 2026. Figures are approximate and can move materially with new raises or spending changes.
Who competes with Ocugen, Inc. (OCGN)?
Ophthalmic gene-therapy developers
Companies such as those advancing AAV-based therapies for inherited retinal disease and AMD compete for patients, trial sites, and investor attention. Ocugen's gene-agnostic modifier approach differs from mutation-specific gene replacement, but several players target overlapping conditions.
Geographic atrophy and AMD treatments
Approved complement-inhibitor therapies for geographic atrophy already exist from larger ophthalmology companies, setting a commercial and efficacy benchmark that OCU410 would need to compete against if it reaches the market.
Small-cap clinical-stage biotech broadly
Ocugen competes with the wider universe of pre-revenue biotechs for capital. Investor appetite for speculative, cash-burning names rises and falls with sentiment, affecting Ocugen's ability to raise money on favorable terms.
What stocks are similar to Ocugen, Inc. (OCGN)?
Other names that sit close to OCGN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Ocugen, Inc. (OCGN)
There are three common ways to get OCGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so OCGN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where OCGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Ocugen, Inc. (OCGN)
If you believe Ocugen's modifier gene-therapy platform can convert promising mid-stage data into approved treatments for retinitis pigmentosa, geographic atrophy, and Stargardt disease, OCGN is one way to express that view, though it is a speculative, pre-revenue biotech whose outcome hinges on binary trial and regulatory events. The opposite case is that clinical-stage biotech is unforgiving: a single failed readout, a regulatory setback, or repeated equity raises can sharply reduce the value of existing shares before any product reaches the market. How those trade-offs sit with you, and how a single high-volatility holding fits the rest of your portfolio, is a personal decision rather than something this page can answer.
More on Ocugen, Inc. (OCGN)
Whether OCGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OCGN a buy or a sell?, and where the stock could go from here in the OCGN stock forecast.
For income investors, whether OCGN pays a dividend and how the payout looks is covered in does OCGN pay a dividend? And to weigh OCGN against a peer, read the full side-by-side comparisons: OCGN vs AMD and OCGN vs HNGE.
Wondering how OCGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Ocugen, Inc.
Ask Walnut's AI anything about OCGN and see how it fits what you own.
FAQ
Is OCGN a good stock to buy right now?
+
That depends on your goals and risk tolerance, and this page does not give advice. The bull case is a maturing gene-therapy pipeline with a lead program heading to Phase 3 topline data in early 2027 and a planned U.S. filing in the second quarter of 2027 and large untapped markets. The bear case is that Ocugen is pre-revenue, burns cash, dilutes shareholders, and faces binary trial risk where a single failure could sharply cut the stock's value. As of October 16, 2026 the stock traded near ~$0.80, below Nasdaq's $1.00 minimum bid level.
What does Ocugen do?
+
Ocugen is a clinical-stage biotechnology company developing gene and cell therapies for eye diseases. Its lead modifier gene-therapy programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy in dry age-related macular degeneration, and OCU410ST for Stargardt disease. The platform aims to treat disease across many genetic mutations rather than targeting a single mutation.
Is OCGN profitable?
+
No. Ocugen is a pre-revenue, clinical-stage company that reports consistent net losses as it funds research and trials. It posted a net loss of roughly $24.9 million in the second quarter of 2026 and ~$81.8 million over the trailing twelve months, and has no approved products generating meaningful sales. Profitability would depend on successfully developing, approving, and commercializing one or more of its therapies.
Does OCGN pay a dividend?
+
No. Ocugen does not pay a dividend. Like most clinical-stage biotechs, it reinvests all available capital into research, clinical trials, and operations rather than returning cash to shareholders. Any return from owning the stock would have to come from share-price appreciation, which is far from guaranteed for a speculative pre-revenue company.
What is OCU400 and why does it matter?
+
OCU400 is Ocugen's lead modifier gene therapy for broad retinitis pigmentosa, based on the NR2E3 nuclear hormone receptor gene. It is gene-agnostic, meaning it aims to help patients regardless of their specific mutation. It completed Phase 3 enrollment in early 2026, with topline Phase 3 data expected in the first quarter of 2027 and a U.S. BLA submission planned for the second quarter of 2027. Outside the U.S., it received provisional approval in the Bahamas in September 2026 and was licensed for the Middle East and North Africa in October 2026.
What happened with Ocugen and the COVID vaccine?
+
Ocugen partnered with India's Bharat Biotech in 2020 to seek U.S. authorization for the COVID-19 vaccine COVAXIN. The program drove large stock swings but faced an FDA clinical hold and never reached U.S. commercial approval. Ocugen has since refocused its primary strategy on ophthalmic gene therapy, though the vaccine history still shapes how some investors view the company.
How can I buy Ocugen stock?
+
OCGN trades on the Nasdaq, so you can buy whole or fractional shares through any major brokerage. Some investors hold it through small-cap or biotech ETFs that include it, or as one position within a thematic basket alongside other names. Because it is volatile and speculative, position sizing relative to your overall portfolio is an important consideration.
Why is OCGN stock so volatile?
+
Ocugen is a pre-revenue biotech whose value rests almost entirely on future clinical and regulatory outcomes. Trial readouts, BLA filings, and agency feedback are binary events that can move the stock sharply in either direction. It also raises capital periodically, which can dilute shareholders. This combination of event-driven upside and cash-burn risk makes the shares prone to large swings.
How has OCGN stock performed in 2026?
+
Poorly. Ocugen closed at ~$0.80 on October 16, 2026, down ~41.7% year to date, ~38.1% over three months and ~50.0% over one year, near the low end of its 52-week range of ~$0.785 to ~$2.725. The decline continued through September and October despite the Bahamas provisional approval and the MENA licensing deal. Walnut is not an investment adviser, and past price moves say nothing certain about future ones.
What is the OCU400 licensing deal in the Middle East and North Africa?
+
On October 14, 2026 Ocugen completed an exclusive license giving Roots Pharmaceutical, with partner Al-Dhow International Holding, OCU400 rights across the MENA region. Ocugen can receive an upfront fee and initial development milestones of up to ~$4 million in aggregate, sales milestones of up to ~$255 million, and royalties equal to 22% of net sales, and it will manufacture commercial supply under a related agreement.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Ocugen, Inc.'s investor relations page or your broker before making investment decisions.